Evidence map›Paper›PMID 35954410›Full record

ArticleCancers2022

Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis.

Evgenii Shumilov, Lena Aperdannier, Nicole Schmidt, Christoph Szuszies, Albrecht Neesse, Petra Hoffknecht, Cyrus Khandanpour, Jan-Henrik Mikesch, Matthias Stelljes, Göran Ramin Boeckel and 13 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 2 countries.

Evgenii ShumilovDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0003-0178-1729
Lena AperdannierDepartment of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
Nicole SchmidtDepartment of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
Christoph SzusziesDepartment of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
Albrecht NeesseDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
Petra HoffknechtDepartment of Thorax Oncology, Franziskus-Hospital Harderberg, Niels-Stensen-Kliniken, 49124 Georgsmarienhütte, Germany.
Cyrus KhandanpourDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0003-4655-6269
Jan-Henrik MikeschDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
Matthias StelljesDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
Göran Ramin BoeckelDepartment of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Münster, Germany.
Phil-Robin TepasseDepartment of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Münster, Germany.ORCID 0000-0002-2757-4755
Lea ReitnauerDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
Raphael KochDepartment of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.ORCID 0000-0002-2018-5685
Justin HasenkampDepartment of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
Ulrike BacherCentral Hematology Laboratory, Department of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0001-8771-947X
Simone ScheithauerDepartment of Infection Control and Infectious Diseases, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.ORCID 0000-0003-0773-4739
Lorenz TrümperDepartment of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
Norbert SchmitzDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
Gerald WulfDepartment of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
Andrea KerkhoffDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
Georg LenzDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
Carolin KrekelerDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
Annalen BleckmannDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
University Hospital Münster · DEUniversitätsmedizin Göttingen · DESt. Franziskus Hospital · DEUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer patients between the pre- and post-vaccine era. We analyzed SARS-CoV-2 infections and their impact on cancer in COVID-19 vaccinated and non-vaccinated patients from three German cancer centers. Overall, 133 patients with SARS-CoV-2 were enrolled in pre- and post-vaccine eras: 84 non-vaccinated and 49 vaccinated, respectively. A mild course of COVID-19 was documented more frequently in vaccinated patients (49% vs. 29%), while the frequency of severe and critical courses occurred in approximately one-half of the non-vaccinated patients (22% vs. 42%,

Indexed as

cancer patientsCOVID-19COVID-19 vaccinationSARS-CoV-2

Identifiers

PMID35954410
PMCPMC9367483
OpenAlexW4289109614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.